Section 03 · Monograph

Pramipexole

Reviewed Nov 2026FDA label

MirapexDopamine agonist

Indications

Treatment of the signs and symptoms of idiopathic Parkinson's disease, effective in both early disease (as monotherapy) and advanced disease (as an adjunct to levodopa)FDA-labeled

Pramipexole is a non-ergot dopamine agonist with high in vitro specificity and affinity for the D2 subfamily of dopamine receptors, binding preferentially to D3 receptor subtypes
Stimulates striatal dopamine receptors, mimicking endogenous dopamine's action to alleviate parkinsonian motor symptoms
Not extensively metabolized; eliminated largely unchanged renally (~90% urinary excretion); terminal half-life ~8 hours in younger patients, ~12 hours in the elderly

Titration schedule: Week 1 — 0.375 mg/day; Week 2 — 0.75 mg/day; Week 3 — 1.5 mg/day; Week 4 — 2.25 mg/day; Week 5 — 3.0 mg/day; Week 6 — 3.75 mg/day; Week 7 — 4.5 mg/day
Effective maintenance range: 1.5–4.5 mg/day in 3 divided doses; maximum recommended dose 4.5 mg/day (1.5 mg three times daily)
Discontinue gradually (taper over 1 week) rather than abruptly to reduce risk of withdrawal symptoms/hyperpyrexia

Immediate-release, normal renal function (CrCl >60 mL/min): start 0.375 mg/day in 3 divided doses; increase no more frequently than every 5–7 days
Renal impairment dose adjustment (immediate-release): CrCl 35–59 mL/min — start 0.125 mg twice daily, max 1.5 mg twice daily; CrCl 15–34 mL/min — start 0.125 mg once daily, max 1.5 mg once daily; CrCl <15 mL/min/hemodialysis — not studied

Cimetidine: inhibits renal tubular secretion, increasing pramipexole AUC by ~50% and half-life by ~40%
Carbidopa-levodopa: no effect on pramipexole kinetics; levodopa Cmax increased ~40% and Tmax shortened when co-administered
Amantadine: may slightly decrease pramipexole clearance
Dopamine antagonists (e.g., antipsychotics, metoclopramide): may diminish pramipexole efficacy
Other drugs eliminated by renal tubular secretion (e.g., diltiazem, verapamil, quinidine, quinine, triamterene): may reduce pramipexole clearance

Impulse control/compulsive behaviors: pathological gambling, hypersexuality, compulsive eating (including binge eating), and compulsive shopping — generally reversible with dose reduction or discontinuation
Somnolence and sudden onset of sleep during activities of daily living, including driving, sometimes without warning signs; more common at doses >1.5 mg/day
Orthostatic hypotension, especially during dose escalation
Hallucinations — early PD 9% vs 2.6% placebo; advanced PD 16.5% vs 3.8% placebo; risk ~6.8-fold higher in patients over 65
Dyskinesia and exacerbation of pre-existing dyskinesia (advanced disease)
Nausea, dizziness, insomnia, constipation, asthenia (early disease)

Continually reassess for daytime drowsiness/sudden sleep episodes, particularly regarding driving safety
Blood pressure monitoring for orthostatic hypotension, especially during dose escalation
Direct, specific screening of patient and caregiver for new or increased gambling, sexual, spending, or eating urges at each visit
Monitor for hallucinations/psychosis, particularly in patients over 65
Renal function at baseline, with dose adjustment for impairment
Periodic dermatologic skin examination for melanoma (increased incidence observed in Parkinson's disease population)

Limited human pregnancy data; animal studies showed embryo resorption and inhibited implantation at clinically relevant doses in rats — use only if potential benefit justifies potential fetal risk
Not known whether pramipexole is excreted in human milk; animal data show drug concentrated in milk 3–6x plasma levels and pramipexole inhibits prolactin secretion, which may impair lactation — decide between discontinuing nursing or discontinuing the drug